Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Female subjects must be of non-child bearing potential.
You may not be if
Clinically significant illness within 2 weeks before the study start.
Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2
Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
Clareo Health | AZD6280 Multiple Ascending Dose Study
